Overview: Retinal Degeneration Age-Related Macular Degeneration Symptoms & Diagnosis Treatment Options Retinitis Pigmentosa Symptoms & Diagnosis Treatment Stargardt Disease Symptoms & Diagnosis Treatment Pipeline Therapeutics (Clinical Stage Products) Comparative Analysis Late Stage Products (Phase III) Comparative Analysis Abicipar: Allergan Product Description Research and Development Product Development Activities (The list continues) Mid Stage Products (Phase II) Comparative Analysis Early Stage Products (Phase I) Comparative Analysis Pre-clinical & Discovery Stage Products Comparative Analysis Therapeutic Assessment: Active Products Assessment by Product Type Assessment by Stage and Product Type Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type Inactive Products Comparative Analysis Appendix

Table 1: Total Products for Retinal Degeneration Table 2: Late Stage Products (Phase III) Table 3: Mid Stage Products (Phase II) Table 4: Early Stage Products (Phase I) Table 5: List of Pre-clinical & Discovery Products Table 6: Assessment by Product Type Table 7: Assessment by Stage and Product Type Table 8: Assessment by Route of Administration Table 9: Assessment by Stage and Route of Administration Table 10: Assessment by Molecule Type Table 11: Assessment by Stage and Molecule Type Table 12: List of Inactive Products Figure 1: Fundus photographs of healthy and AMD affected eyes Figure 2: Fundus photographs of healthy and RP affected eyes Figure 3: Color photo and auto fluorescent fundus image of Stargardt disease Figure 4: Total Products for Retinal Degeneration Figure 5: Late Stage Products (Phase III) Figure 6: Mid Stage Products (Phase II) Figure 7: Early Stage Products (Phase I) Figure 8: Pre-clinical & Discovery Stage Products Figure 9: Assessment by Product Type Figure 10: Assessment by Stage and Product Type Figure 11: Assessment by Route of Administration Figure 12: Assessment by Stage and Route of Administration Figure 13: Assessment by Molecule Type Figure 14: Assessment by Stage and Molecule Type Figure 15: Inactive Products

Aciont Acucela Adalta Adverum Biotechnologies Aerie Pharmaceuticals Aeris Alcon Research Alimera sciences Alkeus Pharmaceuticals Allegro Opthalmics Allergan Altacor Amarantus Apellis Pharmaceuticals Apexigen Applied Genetic Technologies Corporation (AGTC) Ascendis Pharma Astellas Ayuvis Bayer Benitech Biopharma Biolight life sciences BioMAS Biophytis Boehringer Ingelheim Catalyst biosciences Cell Cure Neurosciences Ceregene Charlesson Clanotech Coherus Biosciences CoMentis Daiichi Sankyo Dompé Farmaceutici Exonate Eyevensys Ferrer Genentech Genera Corporation Gensight Biologics GenVec GlaxoSmithKline Graybug Vision Grupo Ferrer Internacional Gyroscope Therapeutics Healios Hemera Biosciences Horama Iconic Therapeutics ID Pharma Inflectis Bioscience Ionis Pharmaceuticals Janssen jCyte Jerini Opthalmic Johnson & Johnson Kalos therapeutics Kodiac Sciences KODIAK Light Sciences Lin Bioscience Lpath Lysoclear/ Ichor Therapeutics M`s science Makindus MeiraGTx Mimetogen Mitotech Pharma Morphosys Nemusbioscince Neurotech Neurotech Pharmaceuticals NightstaRx Novartis Novelion Therapeutics Occurx Ocugen Ocular Therapeutix Odylia Ohr Pharmaceutical Olix OliX Pharmaceuticals Omeros Ophthotech Ophthotech Corporation OPKO Health Opsis Therapeutics Opthea Opthotech Corporation Orphagen Pharmaceuticals Oxford BioMedica Paloma Pharmaceuticals PanOptica Pfizer Phycopharma ProQR ProQR Therapeutics ProRetina ProRetina pSivida Quark Ra Pharma Recursion Pharma Regenerative patch technologies Regeneron REGENXBIO ReNeuron Roche R-Tech Ueno RXI Pharmaceuticals S & I Ophthalmic# Sanofi Santen Santen Pharmaceutical SciFluor Life Sciences Shire Stealth BioTherapeutics Synthetic Biologics Therapeutic Vision ThromboGenics Tyrogenex Vision Medicines